211 related articles for article (PubMed ID: 31188522)
21. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
[TBL] [Abstract][Full Text] [Related]
22. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
[TBL] [Abstract][Full Text] [Related]
23. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
[TBL] [Abstract][Full Text] [Related]
24. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11).
Sibiude J; Mandelbrot L; Blanche S; Le Chenadec J; Boullag-Bonnet N; Faye A; Dollfus C; Tubiana R; Bonnet D; Lelong N; Khoshnood B; Warszawski J
PLoS Med; 2014 Apr; 11(4):e1001635. PubMed ID: 24781315
[TBL] [Abstract][Full Text] [Related]
25. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
26. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
Mohan H; Lenis MG; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
EBioMedicine; 2021 Jan; 63():103167. PubMed ID: 33341441
[TBL] [Abstract][Full Text] [Related]
27. Gestational weight gain and adverse birth outcomes in South African women with HIV on antiretroviral therapy and without HIV: a prospective cohort study.
Madlala HP; Myer L; Jao J; Geffen H; Matjila M; Fisher A; Meyer D; Werner EF; Petro G; Cu-Uvin S; McGarvey ST; Bengtson AM
J Int AIDS Soc; 2024 Jun; 27(6):e26313. PubMed ID: 38926935
[TBL] [Abstract][Full Text] [Related]
28. Use of Dolutegravir for Antiretroviral Therapy for Women of Childbearing Age.
Atkin K; Scannell M; Nicholas PK
J Obstet Gynecol Neonatal Nurs; 2019 Nov; 48(6):664-673. PubMed ID: 31479630
[TBL] [Abstract][Full Text] [Related]
29. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.
Zash R; Makhema J; Shapiro RL
N Engl J Med; 2018 Sep; 379(10):979-981. PubMed ID: 30037297
[No Abstract] [Full Text] [Related]
30. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003.
Townsend CL; Tookey PA; Cortina-Borja M; Peckham CS
J Acquir Immune Defic Syndr; 2006 May; 42(1):91-4. PubMed ID: 16763496
[TBL] [Abstract][Full Text] [Related]
32. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
33. Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
van der Wekken-Pas L; Nassiwa S; Malaba T; Lamorde M; Myer L; Waitt C; Reynolds H; Khoo S; He N; van Leeuwen L; Burger D; Wang D; Colbers A
AIDS; 2024 Jun; 38(7):975-981. PubMed ID: 38277390
[TBL] [Abstract][Full Text] [Related]
34. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.
Romo ML; Patel RC; Edwards JK; Humphrey JM; Musick BS; Bernard C; Maina MW; Brazier E; Castelnuovo B; Penner J; Wyka K; Cardoso SW; Ly PS; Kunzekwenyika C; Cortés CP; Panczak R; Kelvin EA; Wools-Kaloustian KK; Nash D;
Ann Intern Med; 2022 Jan; 175(1):84-94. PubMed ID: 34843382
[TBL] [Abstract][Full Text] [Related]
35. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
Phillips AN; Venter F; Havlir D; Pozniak A; Kuritzkes D; Wensing A; Lundgren JD; De Luca A; Pillay D; Mellors J; Cambiano V; Bansi-Matharu L; Nakagawa F; Kalua T; Jahn A; Apollo T; Mugurungi O; Clayden P; Gupta RK; Barnabas R; Revill P; Cohn J; Bertagnolio S; Calmy A
Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 6-week PMTCT outcomes for HIV-exposed and HIV-unexposed infants in the era of lifelong ART: Results from an observational prospective cohort study.
Tiam A; Kassaye SG; Machekano R; Tukei V; Gill MM; Mokone M; Letsie M; Tsietso M; Seipati I; Barasa J; Isavwa A; Tylleskär T; Guay L
PLoS One; 2019; 14(12):e0226339. PubMed ID: 31877153
[TBL] [Abstract][Full Text] [Related]
37. Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial.
Hill AM; Elbirt D
AIDS; 2024 Jul; 38(9):1430-1431. PubMed ID: 38932745
[No Abstract] [Full Text] [Related]
38. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
Dorenbaum A; Cunningham CK; Gelber RD; Culnane M; Mofenson L; Britto P; Rekacewicz C; Newell ML; Delfraissy JF; Cunningham-Schrader B; Mirochnick M; Sullivan JL;
JAMA; 2002 Jul; 288(2):189-98. PubMed ID: 12095383
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007.
Townsend CL; Willey BA; Cortina-Borja M; Peckham CS; Tookey PA
AIDS; 2009 Feb; 23(4):519-24. PubMed ID: 19165088
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
